Adaptive Biotechnologies Co. (NASDAQ:ADPT) President Sells $923,700.00 in Stock

Adaptive Biotechnologies Co. (NASDAQ:ADPT) President Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, December 28th. The stock was sold at an average price of $61.58, for a total transaction of $923,700.00. Following the completion of the sale, the president now owns 15,000 shares of the company’s stock, valued at $923,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Julie Rubinstein also recently made the following trade(s):

  • On Wednesday, December 30th, Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $59.61, for a total transaction of $894,150.00.
  • On Thursday, December 24th, Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $63.53, for a total transaction of $952,950.00.
  • On Tuesday, December 22nd, Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $63.71, for a total transaction of $955,650.00.

ADPT stock opened at $59.13 on Friday. Adaptive Biotechnologies Co. has a one year low of $15.19 and a one year high of $65.69. The company’s fifty day moving average price is $53.01 and its 200-day moving average price is $46.62. The company has a market capitalization of $8.09 billion, a PE ratio of -62.24 and a beta of 0.28.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Sunday, November 15th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.01. The firm had revenue of $26.30 million for the quarter, compared to the consensus estimate of $23.58 million. Adaptive Biotechnologies had a negative net margin of 132.32% and a negative return on equity of 20.15%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. As a group, equities analysts expect that Adaptive Biotechnologies Co. will post -1.08 EPS for the current fiscal year.

Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $60.00 price target (up previously from $50.00) on shares of Adaptive Biotechnologies in a report on Wednesday, November 11th. Morgan Stanley lifted their price target on shares of Adaptive Biotechnologies from $42.00 to $46.00 and gave the company an “equal weight” rating in a report on Wednesday, November 11th. Finally, BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $60.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, November 12th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Adaptive Biotechnologies has an average rating of “Buy” and an average price target of $54.67.

A number of institutional investors have recently added to or reduced their stakes in the stock. HM Payson & Co. purchased a new stake in Adaptive Biotechnologies during the third quarter valued at $30,000. Strs Ohio raised its stake in Adaptive Biotechnologies by 41.1% during the third quarter. Strs Ohio now owns 18,448 shares of the company’s stock valued at $897,000 after purchasing an additional 5,375 shares in the last quarter. Sei Investments Co. raised its stake in Adaptive Biotechnologies by 5.2% during the third quarter. Sei Investments Co. now owns 119,731 shares of the company’s stock valued at $5,833,000 after purchasing an additional 5,941 shares in the last quarter. Brinker Capital Investments LLC purchased a new stake in Adaptive Biotechnologies during the third quarter valued at $240,000. Finally, Public Employees Retirement System of Ohio raised its stake in Adaptive Biotechnologies by 10.8% during the third quarter. Public Employees Retirement System of Ohio now owns 30,064 shares of the company’s stock valued at $1,462,000 after purchasing an additional 2,936 shares in the last quarter. 73.67% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals.

Read More: Is it better to buy a fund with a higher or lower NAV?

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.